TY - JOUR
T1 - COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study
AU - Lai, Francisco Tsz Tsun
AU - Yan, Vincent Ka Chun
AU - Wan, Eric Yuk Fai
AU - Chan, Cheyenne I. Ying
AU - Wei, Cuiling
AU - Cheng, Franco Wing Tak
AU - Chui, Celine Sze Ling
AU - Li, Xue
AU - Wong, Carlos King Ho
AU - Cheung, Ching Lung
AU - Wong, Ian Chi Kei
AU - Chan, Esther Wai Yin
N1 - Copyright © 2024 The Authors. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/).
PY - 2024/4/19
Y1 - 2024/4/19
N2 - Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.
AB - Multimorbidity entails a higher risk of SARS-CoV-2 infection and COVID-19 complications. We examined vaccine effectiveness (VE) stratified by multimorbidity using a case-control study of territory-wide electronic health records in Hong Kong. Cases of infection (testing positive), hospitalization, and mortality were identified from January to March 2022. Controls were matched by age, sex, outpatient attendance/hospitalization date, and Charlson Comorbidity Index. We demonstrated a consistently good VE among people with increased multimorbidity burden; even more so than among those with minimal such burden. There was also a significantly greater VE after a third dose of BNT162b2 or CoronaVac against infection. The difference in VE between those with multimorbidity and those without was less pronounced for hospitalization, and such difference for COVID-19-related mortality was negligible. In conclusion, VE of both examined vaccines against SARS-CoV-2 infection among people with more complex multimorbidity burden is significant. Further vaccine roll-out should prioritize people with multimorbidity.
UR - https://www.cell.com/iscience/fulltext/S2589-0042(24)00649-7?_returnURL=https%253A%252F%252Flinkinghub.elsevier.com%252Fretrieve%252Fpii%252FS2589004224006497
UR - http://www.scopus.com/inward/record.url?scp=85188077376&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2024.109428
DO - 10.1016/j.isci.2024.109428
M3 - Article
C2 - 38544567
SN - 2589-0042
VL - 27
JO - iScience
JF - iScience
IS - 4
M1 - 109428
ER -